Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-20: Form 8-K; Period of report 2019-12-18; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-12-06: Form 8-K; Period of report 2019-12-05; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-11-26: Form 8-K; Period of report 2019-11-20; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; Details 1.01.
- 2019-11-13: Form 8-K; Period of report 2019-11-13; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-20 | 8-K | 2019-12-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 18, 2019, the Compensation Committee of the Board of Directors of Recro Pharma, Inc. (the “Company”) approved an increase in the annual base salary of Ryan D. Lake, the Company’s Chief Financial Officer and Treasurer, to $400,000 (from $347,200), effective January 1, 2020. | d853909d8k.htm |
| 2019-12-06 | 8-K | 2019-12-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously disclosed, on November 21, 2019, Recro Pharma, Inc. (the “Company”) completed the separation of Baudax Bio, Inc. (the “Separation”) from the Company. | d729804d8k.htm |
| 2019-11-26 | 8-K | 2019-11-20 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets | 1.01 On November 21, 2019, Recro Pharma, Inc. (“Recro” or the “Company”) completed the previously announced separation of its acute care business segment, and certain other assets and liabilities. 2.01 As described above, on November 21, 2019, Recro completed the Separation. | d839891d8k.htm |
| 2019-11-13 | 8-K | 2019-11-13 | 8.01 Other Events | 8.01 On November 13, 2019, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d829687d8k.htm |
| 2019-11-08 | 8-K | 2019-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2019. | d831798d8k.htm |
| 2019-11-05 | 8-K | 2019-11-05 | 8.01 Other Events | 8.01 On November 5, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing the record date and distribution date for the dividend of shares of Baudax Bio, Inc. common stock to be distributed to the Company’s shareholders in connection with the spin-out of the Company’s acute care segment. | d824613d8k.htm |
| 2019-10-31 | 8-K | 2019-10-31 | 8.01 Other Events | 8.01 On October 31, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing it has received a written decision from the U.S. Food and Drug Administration granting its appeal of the Complete Response Letter relating to the New Drug Application seeking approval for intravenous meloxicam. | d816459d8k.htm |
| 2019-10-28 | 8-K | 2019-10-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 22, 2019, Recro Pharma, Inc. (the “Company”) entered into a Third Amendment to Credit Agreement and Release Agreement by and among the Company, the Company’s subsidiaries named as guarantors therein (the “Guarantors”), the lenders named therein (the “Lenders”), and Athyrium Opportunities III Acquisition LP (“Athyrium”), in its capacity as the administrative agent (the “Third Amendment”). | d823873d8k.htm |
| 2019-08-08 | 8-K | 2019-08-08 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 8, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2019. 8.01 On August 8, 2019, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | d788086d8k.htm |
| 2019-05-20 | 8-K | 2019-05-20 | 8.01 Other Events | 8.01 On May 20, 2019, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d723995d8k.htm |
| 2019-05-15 | 8-K | 2019-05-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of May 9, 2019 (the “Separation Date”), Michael Celano is no longer employed as Chief Operating Officer and Secretary of Recro Pharma, Inc. (the “Company”). | d747533d8k.htm |
| 2019-05-10 | 8-K | 2019-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2019. | d730809d8k.htm |
| 2019-04-18 | 8-K | 2019-04-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 On April 15, 2019, Recro Pharma, Inc., through its wholly-owned subsidiary, Recro Gainesville LLC (collectively, the “Company”) entered into Supplemental Agreement No. 3 to the Amended and Restated License and Supply Agreement (the “Supplemental Agreement”) with Watson Laboratories, Inc. (“Watson”), a subsidiary of Teva Pharmaceutical Industries Ltd., effective as of January 1, 2019. | d738594d8k.htm |
| 2019-04-05 | 8-K | 2019-04-03 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 On April 3, 2019, Recro Pharma, Inc. (the “Company”) implemented a strategic restructuring initiative, and corresponding reduction in workforce, aimed at reducing operating expenses, while maintaining key personnel needed to select a partner and obtain U.S. Food and Drug Administration (“FDA”) approval of intravenous (“IV”) meloxicam. 8.01 On April 3, 2019, the Company issued a press release announcing the restructuring initiative and revised CDMO revenue, operating income and EBITDA, as adjusted, guidance for 2019. | d650732d8k.htm |
| 2019-03-28 | 8-K | 2019-03-25 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On March 25, 2019, Recro Pharma, Inc. (the “Company”) entered into an agreement (the “Agreement”) with Engine Capital, L.P., Engine Jet Capital, L.P., Engine Investments, LLC, and Arnaud Ajdler (collectively, “Engine” or the “Investors” and each an “Investor”), regarding appointment of Arnaud Ajdler to the Company’s Board of Directors (the “Board”) and certain other matters. 5.02 The information included above in Item 1.01 is incorporated by reference into this Item 5.02. 8.01 On March 25, 2019, the Company issued a press release announcing the appointment of Mr. Ajdler as a director, a copy of which is filed as Exhibit 99.1 to the Current Report on Form 8-K and incorporated herein by reference. | d691844d8k.htm |
| 2019-03-22 | 8-K | 2019-03-22 | 8.01 Other Events | 8.01 On March 22, 2019, Recro Pharma, Inc. issued a press release announcing the receipt of a Complete Response Letter from the U.S. Food and Drug Administration Office of Drug Evaluation II regarding the New Drug Application for IV meloxicam. | d717868d8k.htm |
| 2019-03-06 | 8-K/A | 2019-02-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 8, 2019, Recro Pharma, Inc., through its wholly-owned subsidiary, Recro Gainesville LLC (collectively, the “Company”) entered into a new Manufacturing and Supply Agreement (the “Agreement”) with Novartis Pharma AG (“Novartis”), effective as of January 1, 2019, pursuant to which the Company will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules (together, the “Products”) through 2023. | d717175d8ka.htm |
| 2019-03-04 | 8-K | 2019-02-28 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On February 28, 2019, Recro Pharma, Inc. (the “Company”) entered into a Second Amendment to Credit Agreement and Investment Documents (the “Second Amendment”) by and among the Company, certain of the Company’s subsidiaries named as guarantors therein (the “Guarantors”), Athyrium Opportunities III Acquisition LP, as a lender and as the administrative agent for the lenders thereunder (“Athyrium”), and the other lenders named therein (the “Lenders”). 2.03 The information set forth under Item 1.01 above is incorporated into this Item 2.03 by reference. | d717515d8k.htm |
| 2019-02-19 | 8-K | 2019-02-19 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On February 19, 2019, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2018. 8.01 On February 19, 2019, The Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | d709329d8k.htm |
| 2019-02-14 | 8-K | 2019-02-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 8, 2019, Recro Pharma, Inc., through its wholly-owned subsidiary, Recro Gainesville LLC (collectively, the “Company”) entered into a new Manufacturing and Supply Agreement (the “Agreement”) with Novartis Pharma AG (“Novartis”), effective as of January 1, 2019, pursuant to which the Company will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules (together, the “Products”) through 2023. | d709803d8k.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 8.01 Other Events | 8.01 On January 7, 2019, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d634085d8k.htm |
| 2019-01-04 | 8-K | 2018-12-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 1.01 On December 28, 2018, Recro Pharma, Inc. (the “Company”) entered into a First Amendment to Credit Agreement and Investment Documents by and among the Company, certain of the Company’s subsidiaries named as guarantors therein (the “Guarantors”), the lenders named therein (the “Lenders”), and Athyrium Opportunities III Acquisition LP (“Athyrium”), in its capacity as the administrative agent (the “First Amendment”). 3.02 The information in Item 1.01 above with regard to the Warrants is incorporated in this Item 3.02 by reference. 3.03 The information in Item 1.01 above with regard to the Warrants is incorporated in this Item 3.03 by reference. | d624954d8k.htm |